Why DexCom, Inc. (DXCM) Stock Rose 12.0% on Jul 31, 2026
What happened
DexCom reported Q2 2026 earnings today beating consensus on both EPS ($0.70 vs. $0.61 expected) and revenue ($1.31B vs. $1.29B expected), while raising full-year 2026 guidance to $5.18–$5.25B driven by strong CGM demand and G7 device adoption (per web_catalyst and earnings filing). Piper Sandler reiterated Overweight and raised its price target from $88 to $95. The stock surged 10.76% to $82.56 on 2.65x elevated volume (6.4M shares, 213 min into session).
DexCom's next scheduled earnings report is 2026-10-29 (consensus EPS estimate: $0.67); monitor for any updates on Q3 CGM demand trends and G7 market penetration.
Other developments that session
DexCom, Inc. (DXCM) reported EPS of $0.70 vs. consensus estimate of $0.61, beating by 14.8% for Q2 FY2026.
Frequently asked questions
Why did DexCom, Inc. (DXCM) stock rise on Jul 31, 2026?
DexCom reported Q2 2026 earnings today beating consensus on both EPS ($0.70 vs. $0.61 expected) and revenue ($1.31B vs. $1.29B expected), while raising full-year 2026 guidance to $5.18–$5.25B driven by strong CGM demand and G7 device adoption (per web_catalyst and earnings filing). Piper Sandler reiterated Overweight and raised its price target from $88 to $95. The stock surged 10.76% to $82.56 on 2.65x elevated volume (6.4M shares, 213 min into session).
How much did DXCM stock rise on Jul 31, 2026?
DXCM rose 12.0% during the Jul 31, 2026 trading session.